Daihan Competitors

Stocks . Korea . 
Stock . Daihan Pharmaceutical CoLtd
023910 Stock  KRW 25,850  50.00  0.19%   
Daihan Pharmaceutical competes with Daejung Chemicals, Duksan Hi, MetaLabs, SV Investment, and Samick Musical; as well as few others. The company operates under Healthcare sector and is part of Pharmaceuticals industry. Analyzing Daihan Pharmaceutical competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Daihan Pharmaceutical to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Daihan Pharmaceutical Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Daihan Pharmaceutical competition on your existing holdings.
  
Hype
Prediction
LowEstimatedHigh
25,79925,80025,801
Details
Intrinsic
Valuation
LowRealHigh
23,98023,98128,380
Details
Naive
Forecast
LowNextHigh
26,08926,09026,091
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
25,52525,86226,200
Details

Daihan Pharmaceutical Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Daihan Pharmaceutical and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Daihan and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Daihan Pharmaceutical does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
077360
+ 0.76
120240
002450
+ 0.72
120240
003230
+ 0.71
120240
289080
+ 0.71
077360
003230
+ 0.68
002450
003230
+ 0.62
077360
  
High negative correlations   
003230
- 0.53
001290
001290
- 0.25
002450
003230
- 0.08
090370
001290
- 0.0
077360

Risk-Adjusted Indicators

There is a big difference between Daihan Stock performing well and Daihan Pharmaceutical Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Daihan Pharmaceutical's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Daihan Pharmaceutical Competitive Analysis

The better you understand Daihan Pharmaceutical competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Daihan Pharmaceutical's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Daihan Pharmaceutical's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
023910 120240 077360 090370 289080 002450 001290 003230
 0.19 
 25,850 
Daihan
 0.38 
 13,180 
Daejung
 0.34 
 4,365 
Duksan
 0.44 
 1,362 
MetaLabs
 0.48 
 1,458 
289080
 0.32 
 1,227 
Samick
 0.24 
 417.00 
Golden
 0.34 
 876,000 
Samyang
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Market Performance
(90 Days Performance)
Very Weak
Modest
Modest
Weak
Insignificant
Modest
Very Weak
Solid
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Low
Low
Below Average
Low
Low
Low
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Sell
Strong Hold
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Buy
Current Ratio
3.12 X
2.26 X
2.43 X
N/A
2.45 X
N/A
N/A
N/A
Net Asset
272.54 B
162.97 B
323.67 B
85.03 B
78.61 B
N/A
N/A
N/A
Profit Margin
0.10 %
0.08 %
0.25 %
(0.59) %
0.30 %
N/A
N/A
N/A
EBITDA
39.72 B
9.05 B
11.41 B
(12.25 B)
N/A
N/A
N/A
N/A
Operating Margin
0.17 %
0.09 %
0.10 %
(0.03) %
0.44 %
N/A
N/A
N/A
Current Valuation
148.23 B
163.81 B
344.19 B
(25.55 B)
212.77 B
N/A
N/A
N/A
Price To Book
N/A
N/A
N/A
0.19 X
N/A
N/A
N/A
N/A
Retained Earnings
67.17 B
47.39 B
172.16 B
N/A
N/A
N/A
N/A
N/A
Current Asset
75.05 B
43.31 B
45.18 B
N/A
N/A
N/A
N/A
N/A
Beta
0.53
1.09
1.26
-0.39
-1.18
N/A
N/A
N/A
Number Of Employees
7
11
194
39
15
N/A
N/A
N/A
Shares Outstanding
6 M
7.1 M
19.96 M
4.98 M
53.23 M
N/A
N/A
N/A
Cash Flow From Operations
40.62 B
9.46 B
(13.65 B)
2.28 B
(4.52 B)
N/A
N/A
N/A
Annual Yield
0.01 %
0.02 %
N/A
N/A
N/A
N/A
N/A
N/A
Total Debt
14 B
477.17 M
1.69 B
N/A
505.93 M
N/A
N/A
N/A
Return On Equity
12.49
10.76
9.53
-0.3
16.5
N/A
N/A
N/A
Z Score
7.8
N/A
42.6
N/A
N/A
N/A
N/A
N/A
Return On Asset
0.0677
0.0295
0.0185
-0.0071
0.13
N/A
N/A
N/A
Current Liabilities
42.01 B
10.54 B
18.57 B
N/A
N/A
N/A
N/A
N/A
Total Asset
272.54 B
162.97 B
323.67 B
85.03 B
78.61 B
N/A
N/A
N/A
Debt To Equity
0.15 %
0.14 %
0.12 %
N/A
N/A
N/A
N/A
N/A
Target Price
58000.0
N/A
13500.0
8070.0
N/A
N/A
N/A
N/A
Last Dividend Paid
N/A
250.0
N/A
N/A
N/A
N/A
N/A
N/A
Shares Owned By Institutions
13.66 %
0.28 %
9.70 %
0.06 %
0.56 %
N/A
N/A
N/A
Market Capitalization
182.1 B
117.16 B
121.35 B
16.76 B
133.09 B
N/A
N/A
N/A
Price To Earning
11.74 X
11.77 X
7.98 X
N/A
N/A
N/A
N/A
N/A
Price To Sales
0.93 X
1.79 X
1.49 X
0.38 X
5.43 X
N/A
N/A
N/A
Net Income
22.67 B
8.45 B
31.73 B
(14.51 B)
10.71 B
N/A
N/A
N/A
Shares Owned By Insiders
34.84 %
51.37 %
57.59 %
55.69 %
27.20 %
N/A
N/A
N/A
Revenue
171.46 B
88.93 B
92.72 B
39.3 B
31.5 B
N/A
N/A
N/A
Working Capital
33.04 B
32.77 B
26.61 B
N/A
N/A
N/A
N/A
N/A
Cash And Equivalents
83.73 B
36.69 B
18.51 B
N/A
7.32 B
N/A
N/A
N/A
Cash Per Share
N/A
N/A
N/A
N/A
145.62 X
N/A
N/A
N/A
Gross Profit
56.19 B
18.57 B
19.53 B
20.13 B
27.56 B
N/A
N/A
N/A
Day Typical Price
25833.33
13143.33
4348.33
1378.67
1454.67
1232.0
419.0
879000.0
Accumulation Distribution
0.0058
49.1
1393.86
1113.11
1487.91
8459.02
6555.61
834.39
Market Facilitation Index
150.0
0.0187
0.001
0.0024
1.0E-4
2.0E-4
1.0E-4
0.59
Daily Balance Of Power
0.3333
0.4545
(0.19)
0.0968
0.3889
(0.08)
0.0714
(0.14)
Period Momentum Indicator
50.0
50.0
(15.00)
6.0
7.0
(4.00)
1.0
(3,000)
Rate Of Daily Change
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
Day Median Price
25825.0
13125.0
4340.0
1387.0
1453.0
1234.5
420.0
880500.0
Price Action Indicator
50.0
80.0
17.5
(22.00)
8.5
(9.50)
(2.50)
(6,000)
Relative Strength Index
51.58
55.64
60.85
57.39
58.59
58.0
48.37
68.82
Coefficient Of Variation
(2,086)
1443.7
1539.91
(89,690)
3053.54
1315.56
(7,705)
442.43
Mean Deviation
0.6798
1.1
2.18
1.78
1.75
1.98
0.9466
2.42
Jensen Alpha
(0.06)
0.1045
0.1688
(0.01)
0.0735
0.2772
(0.03)
0.772
Total Risk Alpha
(0.05)
0.1202
0.1977
0.0086
0.0984
0.3109
(0.02)
0.801
Sortino Ratio
N/A
0.0676
0.0654
N/A
0.0332
0.0956
N/A
0.3787
Downside Variance
N/A
2.75
7.52
N/A
6.09
8.84
N/A
4.21
Standard Deviation
0.9644
1.67
2.82
2.42
2.61
3.78
1.3
3.45
Kurtosis
1.91
4.79
0.5899
1.52
4.59
15.09
2.64
4.59
Potential Upside
1.54
2.4
4.7
3.83
4.61
5.44
1.81
6.36
Treynor Ratio
18.14
(0.66)
(0.27)
0.0389
(0.25)
(3.47)
0.4089
3.71
Maximum Drawdown
4.99
9.54
13.6
10.14
15.93
33.38
8.28
17.34
Variance
0.9301
2.78
7.94
5.87
6.81
14.32
1.69
11.93
Market Risk Adjusted Performance
18.15
(0.65)
(0.26)
0.0489
(0.24)
(3.46)
0.4189
3.72
Risk Adjusted Performance
(0.03)
0.0566
0.0552
0.0061
0.0313
0.064
(0.01)
0.1742
Skewness
0.4133
0.6915
(0.09)
(0.64)
(0.11)
2.09
(0.53)
1.77
Semi Deviation
N/A
1.45
2.54
N/A
2.25
2.57
N/A
1.6
Information Ratio
(0.05)
0.0671
0.0637
(0)
0.0314
0.0751
(0.02)
0.225
Value At Risk
(1.67)
(2.05)
(3.73)
(4.63)
(2.86)
(2.93)
(2.08)
(3.40)
Expected Short fall
N/A
(1.15)
(2.51)
N/A
(2.15)
(2.53)
N/A
(3.22)
Downside Deviation
N/A
1.66
2.74
N/A
2.47
2.97
N/A
2.05
Semi Variance
N/A
2.11
6.47
N/A
5.06
6.61
N/A
2.56

Daihan Pharmaceutical Competition Performance Charts

Five steps to successful analysis of Daihan Pharmaceutical Competition

Daihan Pharmaceutical's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Daihan Pharmaceutical in relation to its competition. Daihan Pharmaceutical's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Daihan Pharmaceutical in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Daihan Pharmaceutical's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Daihan Pharmaceutical, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Daihan Pharmaceutical position

In addition to having Daihan Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Investor Favorites Thematic Idea Now

Investor Favorites
Investor Favorites Theme
Macroaxis most traded equities with largest long positions over the last 2 years. The Investor Favorites theme has 21 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investor Favorites Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Daihan Stock

Daihan Pharmaceutical financial ratios help investors to determine whether Daihan Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Daihan with respect to the benefits of owning Daihan Pharmaceutical security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY